Related Experiment Video
Updated: Aug 6, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
STEMI in a Patient With Aspirin-Induced Angioedema: A Case for Early Desensitization
Georges Namnoum1, Maroun Sfeir1
1Cardiology Department, Institut Mutualiste Montsouris, Paris, France.
Insights
Aspirin desensitization is feasible and safe for patients with ST-segment elevation myocardial infarction (STEMI) and aspirin allergy. This approach enables timely dual antiplatelet therapy, crucial for high-risk cardiac patients.
Area of Science:
- Cardiology
- Allergy and Immunology
Background:
- Inferior ST-segment elevation myocardial infarction (STEMI) requires prompt treatment.
- Aspirin allergy, specifically aspirin-induced angioedema, complicates antithrombotic therapy.
- Guideline-recommended dual antiplatelet therapy (DAPT) is critical post-percutaneous coronary intervention (PCI).
Abstract:
We report a 47-year-old male presenting with inferior ST-segment elevation myocardial infarction (STEMI) and a history of aspirin-induced angioedema. Despite the challenges of antithrombotic management in the context of aspirin allergy, the patient underwent successful primary percutaneous coronary intervention (PCI), followed by early in-hospital aspirin desensitization. This case highlights the feasibility and safety of early desensitization, allowing timely initiation of guideline-recommended dual antiplatelet therapy in a high risk setting.
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome IV: Interprofessional Care
Angina IV: Management
Mitral Stenosis III: Medical Management
Atherosclerosis III: Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
